The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The EGFR Non-Small Cell Lung Cancer Market By 2030 Based On Its 2026 Value?

The egfr non-small cell lung cancer market size has experienced robust expansion in recent years. This market is set to increase from $9.34 billion in 2025 to $10.07 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.8%. The historical rise in market size can be attributed to a higher prevalence of non-small cell lung cancer, innovations in molecular diagnostics, increasing awareness regarding egfr mutation testing, the proliferation of oncology specialty centers, and enhanced accessibility to targeted therapies.

The egfr non-small cell lung cancer market is anticipated to show significant expansion in the upcoming years. It is projected to climb to $13.74 billion in 2030, achieving a compound annual growth rate (CAGR) of 8.1%. This projected growth throughout the forecast period stems from factors such as a developing pipeline of next-generation egfr inhibitors, the increasing implementation of precision oncology strategies, the broadening of biomarker-driven treatment models, the rising incorporation of real-world evidence into oncology practice, and a greater focus on patient-centered cancer management. Noteworthy trends during the forecast period encompass a wider adoption of targeted egfr therapies, increased usage of companion diagnostic testing, an amplified focus on individualized treatment pathways, the expansion of combination therapy approaches, and enhanced integration of multidisciplinary cancer care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33098&type=smp

Which Drivers Are Advancing The EGFR Non-Small Cell Lung Cancer Market Growth?

The escalating focus on tailored medical interventions is projected to fuel the expansion of the epidermal growth factor receptor (EGFR) non-small cell lung cancer market. Personalized medicine represents a healthcare strategy that customizes prevention, diagnosis, and treatment plans according to an individual’s genetic makeup, environmental exposures, and lifestyle elements. The rise of these tailored approaches stems from the improved access to genetic and molecular profiling, which facilitates the precise identification of disease-specific targets and allows for therapies to be adapted for better patient outcomes. Specifically for epidermal growth factor receptor (EGFR) non-small cell lung cancer, personalized medicine helps by identifying particular EGFR mutations in patients, empowering doctors to prescribe targeted treatments that maximize efficacy while minimizing unwanted side effects. For example, in February 2024, the Personalized Medicine Coalition, a US non-profit organization, stated that the FDA granted authorization to 16 novel personalized therapies for rare disease patients in 2023, marking a considerable increase from the six approvals observed in 2022. Thus, the growing emphasis on personalized medicine is a key driver for the epidermal growth factor receptor (EGFR) non-small cell lung cancer market’s growth.

Which Segment-Based Categories Are Covered In The EGFR Non-Small Cell Lung Cancer Market?

The egfr non-small cell lung cancer market covered in this report is segmented –

1) By Drug Type: Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies; Late Phase

2) By Mutation Type: Exon 19 Deletions; Exon 21 L858R Substitution Mutations; Exon 20 Insertion Mutations; Other Mutation Types

3) By Treatment Type: Monotherapy; Combination Therapy

4) By Route of Administration: Oral; Intravenous

5) By End User: Hospitals; Specialty Oncology Centers; Cancer Research Institutes; Academic Institutes; Other End Users

Subsegments:

1) By Tyrosine Kinase Inhibitors: First Generation Tyrosine Kinase Inhibitors; Second Generation Tyrosine Kinase Inhibitors; Third Generation Tyrosine Kinase Inhibitors

2) By Monoclonal Antibodies: Anti Epidermal Growth Factor Receptor Monoclonal Antibodies; Dual Target Monoclonal Antibodies; Antibody Drug Conjugates

3) By Late Phase: Patritumab Deruxtecan; Other Late Phase Pipeline Therapies

Which Trends Are Contributing To Changes In The EGFR Non-Small Cell Lung Cancer Market?

Leading companies in the epidermal growth factor receptor (EGFR) non-small cell lung cancer market are concentrating on developing innovative products, such as antibody drug conjugates, to enhance treatment effectiveness while reducing systemic side effects compared to traditional chemotherapy. An antibody-drug conjugate (ADC) is a therapeutic approach that links a cancer-targeting antibody to a potent drug, enabling the medication to be delivered directly to tumor cells while sparing healthy cells. For instance, in June 2025, AstraZeneca Plc, a UK-based biopharmaceutical company, announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received approval in the U.S. for treating adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have previously undergone EGFR-targeted therapy and platinum-based chemotherapy. This indication was granted accelerated approval based on the observed objective response rate (ORR) and duration of response (DoR), with continued approval contingent on confirmation of clinical benefit in a subsequent trial. The U.S. FDA granted this approval following Priority Review and Breakthrough Therapy Designation. The decision was supported by a subgroup analysis from the TROPION-Lung05 Phase II trial and additional evidence from the TROPION-Lung01 Phase III trial.

Which Key Players Are Active In The EGFR Non-Small Cell Lung Cancer Market?

Major companies operating in the egfr non-small cell lung cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., AstraZeneca Plc, Bayer AG, Eli Lilly and Company, Takeda Pharmaceuticals Company Ltd., Boehringer Ingelheim Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Taiho Pharmaceutical Co. Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd., Betta Pharmaceuticals Co. Ltd., ShanghAI Allist Pharmaceuticals Co. Ltd., Oric Pharmaceuticals Inc., Black Diamond Therapeutics Inc., G1 Therapeutics Inc., Dizal Pharmaceutical, ArriVent BioPharma Inc., and Cullinan Therapeutics Inc.

Access The Complete EGFR Non-Small Cell Lung Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/egfr-non-small-cell-lung-cancer-market-report

Which Region Holds The Largest Share In The EGFR Non-Small Cell Lung Cancer Market?

North America was the largest region in the epidermal growth factor receptor (EGFR) non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egfr non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized EGFR Non-Small Cell Lung Cancer Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model